Argentina is scrambling to keep its soy cargoes flowing to Europe after an unapproved genetically modified strain was detected in shipments, raising the risk of widespread rejections of the country’s most valuable export. Farmers and crushers are going to extra lengths to isolate the drought-resistant soy strain known as HB4 from the rest of the crop, Gustavo Idigoras , president of the Ciara-Cec ...
Argentina is scrambling to keep its soy cargoes flowing to Europe after an unapproved genetically modified strain was detected in shipments, raising the risk of widespread rejections of the country’s most valuable export. Farmers and crushers are going to extra lengths to isolate the drought-resistant soy strain known as HB4 from the rest of the crop, Gustavo Idigoras , president of the Ciara-Cec oilseed processing and export group, said in an interview. While approved in places including Argentina and China, the strain, developed by Bioceres Crop Solutions , lacks authorization in the European Union. The alarm follows recent rejections of Argentine soy meal cargoes by the Netherlands after testing detected the HB4 strain. While the country is the only member of the EU to reject the cargoes so far, it is a primary gateway to the trading bloc. Read More: Netherlands Rejects Argentina Soy Meal Cargoes on GMO Issue “Many of the importers in Europe are paranoid right now,” Idigoras said. Ciara-Cec represents powerhouses of global agriculture trading in Argentina, including Cargill Inc. , Bunge Global SA , and Cofco International Ltd. Bioceres declined to comment. The stakes for Argentina President Javier Milei are significant: Soy exports are projected to have brought in more than $18 billion last year. Milei desperately needs similar inflows from this year’s harvest to rebuild central bank reserves and signal to international bondholders that the cash-strapped nation can meet its debt obligations. Read More: Dollar Deluge Gives Milei Room to Build Reserves: Shock Therapy The HB4 saga comes as the South American Mercosur bloc and the EU provisionally implement a free-trade deal starting this month while the EU’s top court reviews it. The deal was 25 years in the making and faced fierce opposition from European countries with big farming industries. To save the soy trade relationship, Argentina’s industry is effectively placing the HB4 harvest under quarantine. “We are w...
herstockart Coinbase ( COIN ) is set to report its FY26 Q1 earnings on May 7 after the market close. Investors are now closely watching how the company is handling a weaker crypto cycle and internal restructuring. The biggest talking point ahead of results is the company's decision to cut ~14% of its workforce . CEO Brian Armstrong said this move is due to “market cyclicality” and the rapid rise o...
herstockart Coinbase ( COIN ) is set to report its FY26 Q1 earnings on May 7 after the market close. Investors are now closely watching how the company is handling a weaker crypto cycle and internal restructuring. The biggest talking point ahead of results is the company's decision to cut ~14% of its workforce . CEO Brian Armstrong said this move is due to “market cyclicality” and the rapid rise of AI, which is helping smaller teams work faster and more efficiently. Even though the company is financially strong and has multiple revenue streams, the management reported that its business remains volatile QoQ. Armstrong noted the company is preparing to emerge “leaner, faster, and AI-native” for the next growth phase. On the numbers front, analysts expect Q1 EPS of $0.04 and revenue of $1.48B. However, sentiment has weakened sharply, with 24 downward EPS revisions and 26 revenue cuts in the past 3 months—signaling low expectations going into the print. The company’s Q4 results were already weak, with EPS of $0.66 missing by $0.30 and revenue at $1.78B (-21.6% YoY), also below estimates. For Q1, the company guided subscription and services revenue to $550M–$630M (midpoint $590M), well below the consensus of $761M in estimates. Trading activity also looks soft. Coinbase ( COIN ) is down ~13.3% YTD , underperforming the S&P 500’s ( SP500 ) +6.0% gain, and is currently trading ~2% lower near $195. Interestingly, it is also expanding offerings, including launching 24/7 gold and silver futures, signaling diversification beyond cryptocurrency. Currently, SA Quant ratings stand at 2.19 and view it as "sell," while Seeking Alpha analysts and Wall Street analysts rate the stock as "buy." More on Coinbase Coinbase: Bitcoin's Rising Tide Masks A Retail Moat In Structural Decline Coinbase: The 16x EV/Adjusted Ebitda Valuation Remains Attractive Coinbase: Don't Enter Just Yet Coinbase Global cuts headcount by ~14%; stock climbs 4% Crypto stocks inch up post news about compromise on ...
SCM Jeans/iStock Editorial via Getty Images About five months ago, I published my last article about the shipping and supply chain management company United Parcel Service, Inc. ( UPS ). Back in the article I argued that the stock might be cheap for a reason and deserves the low stock price. However, I also made the case that UPS might still be undervalued. In the conclusion of my article I wrote:...
SCM Jeans/iStock Editorial via Getty Images About five months ago, I published my last article about the shipping and supply chain management company United Parcel Service, Inc. ( UPS ). Back in the article I argued that the stock might be cheap for a reason and deserves the low stock price. However, I also made the case that UPS might still be undervalued. In the conclusion of my article I wrote: In my opinion, we can still argue that UPS is slightly undervalued at this point, and the stock might be a solid long-term investment. However, we clearly see UPS struggling right now with revenue and operating income decline, and UPS is trying to reduce its dependency on Amazon as a customer, which has a huge negative impact on the business. UPS might have trouble replacing Amazon as a customer in the next few years, and it remains to be seen how effective the company’s restructuring efforts are. But due to the huge stock price decline – at the time of writing, UPS is still trading 48.5% below its previous all-time high – UPS does not have to be similar profitable as in previous years for the stock to still be fairly valued or even slightly undervalued. Overall, I remain slightly bullish about UPS long-term, but don’t expect the stock to rebound right away. And investors should be prepared for the risk of the dividend being cut – a scenario I would not rule out at this point. Following the article, the stock increased and actually reached a 52-week high around $122 before the stock started to decline again. In particular, the first quarter results, which were reported on April 28, 2026, and the announcement by Amazon.com, Inc. ( AMZN ) to open its logistics services to third-party companies sent the stock down recently. Now, it is trading about 3.5% lower compared to my previous article. In the following article, I will look at UPS from a bearish point of view as well as a bullish point of view and try to determine once again whether the stock might be a good investment a...
Jason Carr/iStock via Getty Images Introduction Occidental Petroleum Corporation ( OXY ) has seen its stock surge on the back of the Iran situation, like many names in the oil & gas industry, since I last rated it a Buy back in September. In all, the stock posted a total return of 24.67% since, vastly outpacing the S&P 500 ( SP500 ) return of 8.98% during that time. With the recent earnings as wel...
Jason Carr/iStock via Getty Images Introduction Occidental Petroleum Corporation ( OXY ) has seen its stock surge on the back of the Iran situation, like many names in the oil & gas industry, since I last rated it a Buy back in September. In all, the stock posted a total return of 24.67% since, vastly outpacing the S&P 500 ( SP500 ) return of 8.98% during that time. With the recent earnings as well as the tensions easing in the Middle East, I want to dive into what the setup looks like right now. Q1 Review Occidental Petroleum posted a mixed set of earnings as revenue came out to $5.23B, a miss of $440MM and an 8.4% Y/Y decrease. On the bottom line, OXY posted a Non-GAAP EPS of $1.06, a massive beat of 47 cents. So, how come the bottom line rose so much? Well, that’s based on 3 distinct factors, with the first being the midstream and market adj. income surging to $591MM from $237MM in Q4, thanks to crude margin timing benefits and gas transportation capacity optimization. The effective tax rate also dropped to 26% from 35% over the previous quarter, contributing roughly 10 to 12 cents of EPS upside. Permian production also beat expectations at 787 Mboed, supporting the realized oil price strength. Thanks to the proceeds of the OxyChem sale , that’s why total net income reached $3.2B for the quarter. Though one thing that majorly surprised me has been the reported negative free cash flow that stood at -$112MM in the quarter compared to $466MM last year, which is quite astonishing when considering the differences in crude prices. Management has attributed this to a $1.8B working capital drag, sharply higher trade receivables driven by the late-quarter spike in prices, and a seasonal Q1 cash demand. On a pre-working capital basis, FCF was a healthy $1.7B. But the consensus full-year FCF estimate is at around $7B, meaning that Oxy requires the working capital reversal to come through cleanly in the remainder of the year. If I’m being honest, the financial performance du...
Lucid Group (NASDAQ:LCID) saw its Morgan Stanley price target cut in half to $5 from $10 on May 6, with the firm keeping its Underweight rating. The cut follows a 29-day stop-sale on the Gravity SUV tied to a supplier quality issue, suspension of full-year guidance, and an unresolved CEO transition. For LCID stock investors, ... Morgan Stanley Slashes Lucid Price Target in Half: Stop-Sale, CEO Hun...
Lucid Group (NASDAQ:LCID) saw its Morgan Stanley price target cut in half to $5 from $10 on May 6, with the firm keeping its Underweight rating. The cut follows a 29-day stop-sale on the Gravity SUV tied to a supplier quality issue, suspension of full-year guidance, and an unresolved CEO transition. For LCID stock investors, ... Morgan Stanley Slashes Lucid Price Target in Half: Stop-Sale, CEO Hunt Spell Deep Trouble
jaanalisette/iStock Editorial via Getty Images Banco Santander ( SAN ) is exploring hedging a portfolio of buy now, pay later loans through the booming market for significant risk transfers, or SRTs, according to a media report on Wednesday. The lender is in talks with investors for an SRT linked to ~€500M ($588M) of loans its digital banking arm made to clients in Germany, Bloomberg News reported...
jaanalisette/iStock Editorial via Getty Images Banco Santander ( SAN ) is exploring hedging a portfolio of buy now, pay later loans through the booming market for significant risk transfers, or SRTs, according to a media report on Wednesday. The lender is in talks with investors for an SRT linked to ~€500M ($588M) of loans its digital banking arm made to clients in Germany, Bloomberg News reported, citing people familiar with the matter. The terms of the potential deal could change as the process continues, they said. Banco Santander ( SAN ) stock rose 4.3% in midday trading. The use of SRTs has surged as European and North American banks seek to shift risks linked to corporate lending amid strong demand from pension managers and hedge funds. Financial institutions are also using the vehicles to manage riskier parts of their balance sheet, such as consumer credit and commercial real estate, Bloomberg noted. While Santander ( SAN ) has been among the most active in issuing SRTs, the potential transaction would be its first tied to buy now, pay later loans, which are often interest-free installment loans that allow consumers to split the payments of purchases. More on Banco Santander Banco Santander, S.A. 2026 Q1 - Results - Earnings Call Presentation Banco Santander, S.A. (SAN) Q1 2026 Earnings Call Transcript Banco Santander, S.A. 2026 Q1 - Results - Earnings Call Presentation Banco Santander Q1 results lifted by disposal gain Santander stock down as bank suspends stock repurchases on pending Webster acquisition
In this article NVO NVO Follow your favorite stocks CREATE FREE ACCOUNT Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday. "If our ambition is to help hundreds of millions of patients out there, then we need not just the best, but the broadest pipeline in the world," said Novo Nordisk CEO Mike Doustdar. "So let's go...
In this article NVO NVO Follow your favorite stocks CREATE FREE ACCOUNT Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in an interview with CNBC on Wednesday. "If our ambition is to help hundreds of millions of patients out there, then we need not just the best, but the broadest pipeline in the world," said Novo Nordisk CEO Mike Doustdar. "So let's go and see who else basically has assets that are complementary to what we have. And we are quite active with those [business development] talks and acquisitions, and you'll see more of those as well going forward." Novo created the market for GLP-1 weight loss drugs with its weekly shots Ozempic and Wegovy. More recently, the company has faced concerns from analysts about whether Novo's pipeline is robust enough for it to remain a leader in the increasingly competitive obesity drug space. Mike Doustdar, chief executive officer of Novo Nordisk A/S, during an interview in New York, US, on Wednesday, Feb. 11, 2026. Michael Nagle | Bloomberg | Getty Images Rival Eli Lilly has already overtaken Novo in market share for weekly GLP-1 shots, though Novo has taken an early lead in the new category of GLP-1 pills for weight loss. Doustdar said he disagrees with the concerns about Novo's upcoming treatments, arguing the drugmaker has "one of the best pipelines in the industry." He pointed to Novo's CagriSema, a drug candidate that targets GLP-1 and amylin, that Novo hopes will be approved at the end of this year, and an experimental amylin-targeting drug called zenagamtide that Novo has accelerated development of, among other assets. "Of course, there's a lot of things in my pipeline that right now I have the privy to look into and get excited (about) but not have shared it yet with the world," he said. "So I am incredibly excited about our pipeline, and I would just say to the investors who are a little bit skeptical, wait and see." Doustdar spoke to CNBC after the company said its We...